

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 7 NOVEMBER 2022

References are made to the notice of the extraordinary general meeting (the “**EGM**”) and the circular of the EGM (the “**Circular**”) both dated 21 October 2022 of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The EGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Monday, 7 November 2022 at 10:00 a.m.. The EGM was held in accordance with the requirements of the PRC Company Law and the Articles.

As at the date of the EGM, the total number of issued shares of the Company was 399,398,420, including 288,616,500 Unlisted Shares and 110,781,920 H Shares, all of which entitled the holders to attend the EGM and vote for or against or abstain from voting on the resolutions (the “**Resolution(s)**”) proposed at the EGM. A total of 20 Shareholders and their proxies holding an aggregate of 342,655,200 voting Shares, representing approximately 85.79% of the total number of voting Shares, attended the EGM. All the Directors, the Supervisors, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication.

No Shareholder was required to abstain from voting on any of the Resolutions in accordance with the requirements of the Listing Rules. There were no Shares entitling the holder(s) to attend the EGM but abstain from voting in favour of any of the Resolutions under Rule 13.40 of the Listing Rules. None of the Shareholders had stated his/her/its intention to vote against or to abstain from voting on any of the Resolutions. The Company was not aware of any Shareholders indicating their intention to vote against any of the Resolutions or abstain from voting at the EGM. All Resolutions were put to vote by way of poll.

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and one Supervisor, were appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the Resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the appointment of Ms. Zhang Leidi as a non-executive Director	342,655,200 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the appointment of Dr. Yao Jiawei as a Supervisor	342,655,200 (100.00%)	0 (0.00%)	0 (0.00%)
SPECIAL RESOLUTIONS		No. of Votes (%)		
		For	Against	Abstain
3.	To consider and approve the adoption of the Share Award Scheme	342,655,200 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the authorization to the Board to deal with matters in relation to the Share Award Scheme	342,655,200 (100.00%)	0 (0.00%)	0 (0.00%)

As more than 50% of votes were cast in favour of each of the above ordinary Resolutions and more than two-thirds of the votes were cast in favour of the above special Resolutions, all of the above Resolutions were duly passed at the EGM.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Zhang Leidi (張蕾娣) was duly appointed as a non-executive Director at the EGM for a term commencing from the conclusion of the EGM and ending on the expiry of the current session of the Board.

The biographical details of Ms. Zhang are set out in the Circular and the announcement dated 17 October 2022 in relation to, inter alia, the proposed change of non-executive Director and proposed change of composition of the Strategy Development Committee.

APPOINTMENT OF SUPERVISOR

The Board is pleased to announce that Dr. Yao Jiawei (姚佳維) was duly appointed as a Supervisor at the EGM for a term commencing from the conclusion of the EGM and ending on the expiry of the current session of the Supervisory Committee.

The biographical details of Dr. Yao are set out in the Circular and the announcement dated 17 October 2022 in relation to, inter alia, the proposed change of Supervisor.

ADOPTION OF THE SHARE AWARD SCHEME

References are made to the Circular and the announcement of the Company dated 17 October 2022 in relation to, inter alia, the proposed adoption of the Share Award Scheme. The Board is pleased to announce that the proposed adoption of the Share Award Scheme was duly approved by the Shareholders at the EGM and the Share Award Scheme will take effect from 7 November 2022.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, 7 November 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.